Reenie McCarthy, Stealth BioTherapeutics CEO
Rare disease drugmaker files for approval despite objections from FDA on adequate trial data
Another small biotech attacking a super-rare disease is leveraging a patient community and very limited clinical data to try to win an FDA approval. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
